MabVax Therapeutics Holdings, Inc. (MBVXQ) Financial Statements (2024 and earlier)

Company Profile

Business Address 11535 SORRENTO VALLEY ROAD
SAN DIEGO, CA 92121
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

9/30/2018
MRQ
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
12/31/2012
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments 8863,9794,0841,4772,2294,747
Cash and cash equivalents 8863,9794,0841,4772,2294,747
Receivables   758   
Prepaid expense 150282420335 
Prepaid expense and other current assets626
Other current assets 171334815 
Other undisclosed current assets    843815
Total current assets: 1,2084,2945,3091,9112,6105,378
Noncurrent Assets
Property, plant and equipment 57873213557  
Intangible assets, net (including goodwill) 6,8266,8266,8266,826
Goodwill 6,8266,8266,8266,826  
Deposits noncurrent assets    11  
Restricted cash and investments      250
Other noncurrent assets 17916912711 
Other undisclosed noncurrent assets    (11)  
Total noncurrent assets: 7,5837,7267,0886,894 250
TOTAL ASSETS: 8,79012,02012,3978,8052,6105,628
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities 3,1113,1783,9562,038364945
Interest and dividends payable 3951    
Employee-related liabilities 312771563230175313
Accounts payable 1,0911,1383,0021,31320151
Accrued liabilities 1,6691,219391494169481
Debt 1,7001,607    
Deferred revenue and credits     4
Other undisclosed current liabilities 9959061,0029285911,176
Total current liabilities: 5,8065,6914,9582,9669552,125
Noncurrent Liabilities
Long-term debt and lease obligation 1,6672,843    
Long-term debt, excluding current maturities 1,6212,775    
Capital lease obligations 4668    
Liabilities, other than long-term debt 186144   441
Restructuring reserve      441
Other liabilities 186144    
Total noncurrent liabilities: 1,8542,987   441
Total liabilities: 7,6608,6784,9582,9669552,566
Temporary equity, carrying amount    1,838  
Equity
Equity, attributable to parent, including: 1,1303,3437,4394,0011,6553,062
Common stock 696328428  
Additional paid in capital 112,10581,53467,75424,492555,139551,335
Accumulated deficit (111,054)(78,262)(60,602)(24,550)(553,530)(548,300)
Other undisclosed equity, attributable to parent 10824,0314627
Total equity: 1,1303,3437,4394,0011,6553,062
TOTAL LIABILITIES AND EQUITY: 8,79012,02012,3978,8052,6105,628

Income Statement (P&L) ($ in thousands)

9/30/2018
TTM
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
12/31/2012
Revenues
(Revenue, Net)
  1481,267314  
Gross profit:  1481,267314  
Operating expenses (18,070)(16,811)(19,392)(8,707)(5,241)(7,979)
Operating loss: (18,070)(16,663)(18,125)(8,393)(5,241)(7,979)
Nonoperating income (expense)
(Other Nonoperating Income (Expense))
 (950)(997)(0)(0)118
Interest and debt expense (929)(997)    
Loss from continuing operations: (19,950)(18,658)(18,125)(8,393)(5,230)(7,971)
Loss before gain (loss) on sale of properties: (19,950)(18,658)(18,125)(8,393)(5,230)(7,971)
Net loss: (19,950)(18,658)(18,125)(8,393)(5,230)(7,971)
Other undisclosed net income attributable to parent 92999720475  
Net loss attributable to parent: (19,021)(17,660)(18,105)(7,918)(5,230)(7,971)
Preferred stock dividends and other adjustments   (9,111)(2,660)  
Other undisclosed net loss available to common stockholders, basic (13,771) (8,835)   
Net loss available to common stockholders, diluted: (32,791)(17,660)(36,051)(10,578)(5,230)(7,971)

Comprehensive Income ($ in thousands)

9/30/2018
TTM
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
12/31/2012
Net loss: (19,950)(18,658)(18,125)(8,393)(5,230)(7,971)
Comprehensive loss, net of tax, attributable to parent: (19,950)(18,658)(18,125)(8,393)(5,230)(7,971)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: